JP2006501201A - 化合物、組成物および方法 - Google Patents

化合物、組成物および方法 Download PDF

Info

Publication number
JP2006501201A
JP2006501201A JP2004523405A JP2004523405A JP2006501201A JP 2006501201 A JP2006501201 A JP 2006501201A JP 2004523405 A JP2004523405 A JP 2004523405A JP 2004523405 A JP2004523405 A JP 2004523405A JP 2006501201 A JP2006501201 A JP 2006501201A
Authority
JP
Japan
Prior art keywords
optionally substituted
benzyl
compound
chloro
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004523405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501201A5 (enExample
Inventor
バーグネス，ギュスターヴ
スミス，ホイットニー，ダブリュ．
ヤオ，ビン
モーガンズ，デヴィッド，ジェイ．，ジュニア
マクドナルド，アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of JP2006501201A publication Critical patent/JP2006501201A/ja
Publication of JP2006501201A5 publication Critical patent/JP2006501201A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004523405A 2002-07-23 2003-07-23 化合物、組成物および方法 Pending JP2006501201A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39822402P 2002-07-23 2002-07-23
PCT/US2003/023319 WO2004009036A2 (en) 2002-07-23 2003-07-23 Compounds compositions and methods

Publications (2)

Publication Number Publication Date
JP2006501201A true JP2006501201A (ja) 2006-01-12
JP2006501201A5 JP2006501201A5 (enExample) 2006-07-13

Family

ID=30771199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004523405A Pending JP2006501201A (ja) 2002-07-23 2003-07-23 化合物、組成物および方法

Country Status (5)

Country Link
US (2) US7211580B2 (enExample)
EP (1) EP1537089A4 (enExample)
JP (1) JP2006501201A (enExample)
AU (1) AU2003256805A1 (enExample)
WO (1) WO2004009036A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540525A (ja) * 2007-09-26 2010-12-24 セルジーン コーポレイション ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
JP2013545744A (ja) * 2010-11-10 2013-12-26 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬として有用なラクタム誘導体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006515886A (ja) * 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
DE602005008953D1 (de) 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
EP1807399A2 (en) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
MX2009005071A (es) 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
GEP20125415B (en) 2007-01-05 2012-03-12 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (enExample) * 1963-05-18
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4281127A (en) * 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0333118Y2 (enExample) 1986-02-20 1991-07-12
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4670560A (en) * 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
US4729996A (en) * 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4808590A (en) * 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
ATE113953T1 (de) 1988-05-10 1994-11-15 Ici Plc Cephalosporine, verfahren zu ihrer herstellung und pharmazeutische präparate.
GB8820129D0 (en) 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
WO1991012001A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
AU640016B2 (en) * 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0481614A1 (en) * 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
RU2104279C1 (ru) 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
AU4376893A (en) 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
JPH06148835A (ja) 1992-11-04 1994-05-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその処理方法
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5401745A (en) 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) * 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US5589489A (en) 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
AU1831395A (en) * 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
JPH09511496A (ja) * 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (ja) * 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
US5891879A (en) * 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
HUP9801828A3 (en) 1995-03-14 2001-02-28 Novartis Ag Benzoic acid, quinoline and quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1996039403A1 (en) 1995-06-05 1996-12-12 Neurogen Corporation 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands
US6245768B1 (en) * 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CN1090621C (zh) * 1995-08-30 2002-09-11 株式会社大冢制药厂 制备喹唑啉－4－酮衍生物的方法
WO1997010221A1 (en) 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
BR9709085A (pt) * 1996-05-15 1999-08-03 Pfizer Novas 2,3-dissubstituído-4(3H)-quinazolinonas
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
BR9714222A (pt) 1996-12-17 2000-04-18 Du Pont Método para o controle de doenças de plantas
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
ES2245015T3 (es) 1997-06-09 2005-12-16 Pfizer Products Inc. Quinazolin-4-onas como antagonistas de ampa.
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
DE69842109D1 (de) 1997-08-21 2011-03-10 Shiseido Co Ltd Chinazolin-4-on Derivate, deren Herstellung und deren Verwendung als Haarwuchsmittel oder in äusserlich anzuwendenden Hautpflegemitteln
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
JP2002500190A (ja) * 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
WO2000000491A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
WO2000007017A2 (en) 1998-07-27 2000-02-10 President And Fellows Of Harvard College Method of high-throughput screening
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6197488B1 (en) 1999-07-21 2001-03-06 Eastman Kodak Company Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity
US6559160B1 (en) * 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
WO2001023364A1 (en) 1999-09-28 2001-04-05 Merck Patent Gmbh Quinazolinones
KR20020047186A (ko) 1999-09-28 2002-06-21 플레믹 크리스티안 퀴나졸리논
AU7734700A (en) 1999-10-01 2001-05-10 Advanced Medicine, Inc. Macrocyclic quinazolinones and their use as local anesthetics
EP1226129B1 (en) 1999-10-27 2006-05-24 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6380205B1 (en) * 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2159488B1 (es) 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.
AU2001249262A1 (en) 2000-03-20 2001-10-03 Sepracor, Inc. Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001074344A2 (en) 2000-03-30 2001-10-11 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
CN1446080A (zh) 2000-06-09 2003-10-01 Osi药物公司 脂质体苯并喹唑啉胸苷酸合成酶抑制剂制剂
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1174430A1 (en) 2000-07-20 2002-01-23 Universität Konstanz Process for the preparation of heterocycles by using C1-building blocks
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
EP1309596B1 (en) 2000-08-11 2008-02-06 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2004529918A (ja) * 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
US7365199B2 (en) * 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US20030220338A1 (en) 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
US6596723B1 (en) * 2001-07-16 2003-07-22 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1425016B1 (en) 2001-09-05 2010-06-02 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
CA2459584A1 (en) 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
DE122009000048I1 (de) 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043961A2 (en) 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
AU2002346471A1 (en) * 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
CA2467916A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE60336901D1 (de) 2002-03-07 2011-06-09 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
EP1492487B1 (en) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003084544A2 (en) 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
AU2003276005B2 (en) 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
EP1531813A1 (en) 2002-07-10 2005-05-25 Applied Research Systems ARS Holding N.V. Use of compounds for increasing spermatozoa motility
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2004022554A1 (en) 2002-09-07 2004-03-18 Celltech R & D Limited Quinazolinone derivatives
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
PT1601673E (pt) 2003-03-07 2009-07-29 Astrazeneca Ab Heterociclos fundidos e suas utilizações
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
AU2004272104B2 (en) * 2003-09-10 2011-09-08 Icagen, Inc Fused ring heterocycles as potassium channel modulators
SI1689724T1 (sl) 2003-11-25 2012-04-30 Novartis Ag Spojine kinazolinona kot sredstva proti raku
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540525A (ja) * 2007-09-26 2010-12-24 セルジーン コーポレイション ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
JP2013545744A (ja) * 2010-11-10 2013-12-26 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬として有用なラクタム誘導体

Also Published As

Publication number Publication date
US7211580B2 (en) 2007-05-01
WO2004009036A3 (en) 2004-08-19
EP1537089A2 (en) 2005-06-08
US20080021050A1 (en) 2008-01-24
US20040142949A1 (en) 2004-07-22
AU2003256805A1 (en) 2004-02-09
AU2003256805A8 (en) 2004-02-09
EP1537089A4 (en) 2008-04-16
WO2004009036A2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
US7332498B2 (en) Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives
US20080021050A1 (en) Compounds, compositions, and methods
US20040048853A1 (en) Compounds, compositions, and methods
US7214800B2 (en) Compounds, compositions, and methods
CN100381428C (zh) 喹唑啉酮类化合物及应用
US7557115B2 (en) Compounds, compositions, and methods
JP4854906B2 (ja) キナゾリノンを用いた方法並びに組成
US20070254870A1 (en) Compounds, compositions and methods
US20040082567A1 (en) Compounds, compositions, and methods
US20050148593A1 (en) Compounds, compositions, and methods
JP2007500213A (ja) 化合物、組成物および方法
US20050197327A1 (en) Compounds, compositions, and methods
CN101302204A (zh) 喹唑啉酮类化合物、包含该化合物的组合物及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420